Skip to main content
. 2009 Jan 16;11(3):229–237. doi: 10.1093/eurjhf/hfn049

Figure 3.

Figure 3

Echocardiographic findings. (A) Representative M-mode echocardiographic findings. Non-treated EAM rats (Group C14) showed reduced left ventricular ejection fraction (LVEF) and pericardial effusion on Day 14. Recombinant S100A8/A9 administration from Days 8 to 13 (Group S14) improved LVEF and suppressed pericardial effusion. (B) EF (%) in Groups N14, C14, S14, N21, C21, and S21. *P < 0.05; **P < 0.01.